Researchers analyzed data from 10 clinical trials to see if a new type of experimental drug could help treat schizophrenia. These drugs, called mGluR agonists and positive allosteric modulators, were tested on 3,715 people with schizophrenia and compared against either a placebo (an inactive pill) or standard antipsychotic medications. The main goal was to see if the new drugs could reduce overall symptom severity, measured by a standard scale called PANSS-Total.
The analysis found that the experimental mGluR drugs did not lead to significantly greater improvement in overall symptoms, specific symptom clusters, or clinicians' global impressions compared to the control groups. While the overall rate of side effects was similar, people taking the experimental drugs were more likely to stop treatment because of adverse events. The certainty of this evidence from the combined studies ranged from high to low.
It's important to understand that this review looked at specific drugs in this class (like pomaglumetad methionil and AZD8529) as they were tested in these particular trials. The results do not mean all future drugs targeting this system will fail, but they show these specific versions did not work better than existing treatments for the broad population studied. For people with schizophrenia and their doctors, this analysis provides clear evidence that these particular experimental options, in their current form, are not superior to standard care and may be less tolerable.